Lung Cancer | Specialty

Bunn Breaks Down the Latest With Antibody-Drug Conjugates in Lung Cancer

July 24th 2020

Although antibody-drug conjugates have yet to receive regulatory approval in the lung cancer space, several emerging agents are showing early promise in clinical trials.

Moving Toward Newfound Diagnostic, Treatment Paradigms in Lung Cancer

July 23rd 2020

Ignacio I. Wistuba, MD, discusses the clinical importance of histological subtyping of lung cancer and additional parameters such as driver alterations, alternative methods for molecular testing, and immunotherapy-related biomarkers have strengthened the diagnostic and treatment paradigms in lung cancer.

New Tools Support Translational Strides in NSCLC

July 23rd 2020

In non–small cell lung cancer, single cell analytics, genome editing, and next-generation animal models represent just some of the modern modalities advancing translational research.

Adjuvant Osimertinib Possesses Potential to Revolutionize NSCLC Treatment, But Longer Follow-Up Needed

July 23rd 2020

The disease-free survival benefit observed with the third-generation EGFR TKI osimertinib as an adjuvant treatment in patients with EGFR-mutant non–small cell lung cancer in the phase 3 ADAURA trial is striking.

Dr. Aggarwal on Emerging Treatment Approaches in ALK+ NSCLC

July 23rd 2020

Charu Aggarwal, MD, MPH, discusses emerging treatment approaches in ALK-positive non–small cell lung cancer.

Dr. Gandara on the Utility of TMB in NSCLC

July 23rd 2020

David R. Gandara, MD, discusses the utility of tumor mutational burden in non–small cell lung cancer.

Examining ADAURA and the Advantages of Adjuvant Osimertinib in EGFR+ NSCLC

July 23rd 2020

In our exclusive interview, Dr. Aggarwal, Dr. Sequist, and Dr. Pennell provided perspective on the results of the ADAURA trial and addressed the potential clinical and financial concerns of using osimertinib in the adjuvant setting in patients with EGFR-mutant NSCLC.

CCC-19 Registry Data Show Increased COVID-19–Associated Mortality in Patients With Cancer

July 22nd 2020

The mortality rate with COVID-19 appears to be higher in patients with cancer—especially those with lung cancer—compared with the general population, and several factors associated with mortality are beginning to emerge.

Pyrotinib Yields Promising Efficacy and Tolerability Among HER2-Altered Solid Tumors

July 16th 2020

The investigational TKI pyrotinib demonstrated encouraging antitumor activity and a manageable toxicity profile in patients with heavily pretreated HER2-mutant non–small cell lung cancer, as well as other advanced solid tumors harboring activating HER2 alterations.

Ramucirumab Combination Expands Lung Cancer Options

July 16th 2020

Edgardo Santos, MD, discusses the FDA approval of ramucirumab plus erlotinib for the first-line treatment of patients with metastatic NSCLC with EGFR exon 19 deletions or exon 21 (L858R) mutations.

NSCLC Management: Second-Line Options

July 16th 2020

Squamous Cell Frontline Therapy: IMpower 131, KEYNOTE-407

July 16th 2020

CheckMate 817 Overview

July 16th 2020

PD-L1 Combination Therapy Clinical Trials

July 16th 2020

Frontline PD-L1 Monotherapy: KEYNOTE-042 and IMpower110

July 16th 2020

CheckMate-9LA: Histology and Frontline Impact

July 16th 2020

Recent Combination Approval: CheckMate-9LA Regimen

July 16th 2020

CheckMate-227 Regimen Safety Profile

July 16th 2020

ASCO 2020 Data Update: CheckMate 227

July 16th 2020

Nondriver Adenocarcinoma: Determining Therapy

July 16th 2020